Research achievements in child psychiatry, adolescent psychiatry, psychosomatic medicine, and psychotherapy, 2003-2008: Schizophrenia;Forschungsleistung der deutschen kinder- und jugendpsychiatrie, psychosomatik und psychotherapie 2003-2008: Schizophrenie

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 37, Issue 4, 2009, Pages 335-340

  Schimmelmann, Benno Graf ^a   Dittmann, Ralf ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ESTROGEN; FLUPENTIXOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

ANTISOCIAL BEHAVIOR; BORDERLINE STATE; CLINICAL TRIAL; DELUSIONAL DISORDER; DISSOCIATIVE DISORDER; DRUG MONITORING; ELECTROENCEPHALOGRAM; HUMAN; MENSTRUAL CYCLE; PERSONALITY DISORDER; PSYCHOANALYSIS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; ADOLESCENT; ADULT; CHILD; COMORBIDITY; FOLLOW UP; GENETICS; PHENOTYPE; PROGNOSIS; PSYCHOLOGY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; COMORBIDITY; FOLLOW-UP STUDIES; HUMANS; PHENOTYPE; PROGNOSIS; PSYCHOTHERAPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 70349229251     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Bachmann C, Haberhausen M, Heinzel-Gutenbrunner M, Remschmidt H, Theisen FM: Large intraindividual variability of olanzapine serum concentrations in adolescents. Therapeutic Drug Monitoring 2008; 30: 108-112
2. Bachmann C, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H, Theisen FM: Large variability of aripiprazole and dehydroaripiprazole serum concentrations in patients with schizophrenia. Therapeutic Drug Monitoring 2008; 30: 462-466
3. Barth GM, Karle M: Grenzerfahrungen und -erleben in psychotischen Zuständen bei Jugendlichen und ihre Verarbeitung. In: Klosinski G (Hrsg.): Grenz- und Extremerfahrungen im interdisziplinären Dialog. Attempto Verlag Tübingen, 2003; 189-221.
4. Beer F, Heinrich H, Springer S, Rüth U, Freisleder FJ: Quetiapine in the treatment of psychotic adolescents: a case series of 23 patients with severe early onset psychosis. World J Biol Psychiatry 2007; 8: 38-41. (Pubitemid 46291200)
5. Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, Vorbach EU, Kühn KU, Lambert M, Dittmann RW, Naber D: Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, doubleblind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol 2006; 9: 135-145. (Pubitemid 43255827)
6. Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, Vorbach EU, Kühn KU, Lambert M, Dittmann RW, Naber D: Does atypical antipsychotic medication improve executive function in schizophrenia? (Letter to the editor). Int J Neuropsychopharmacol 2006; 6: 1-2.
7. Bergemann N, Mundt C, Parzer P, Jannakos I, Nagl I, Salbach B, Klinga K, Runnebaum B, Resch F: Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005; 73: 357-366 (Pubitemid 40093900)
8. Bergemann N, Mundt C, Parzer P, Pakrasi M, Echstein-Mannsperger U, Haisch S, Salbach B, Klinga K, Runnebaum B, Resch F: Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res 2005; 74: 125-134 (Pubitemid 40255071)
9. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C: Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007; 37: 1427-1436 (Pubitemid 47581417)
10. Brunner R, Parzer P, Schmitt R, Resch F: Dissociative symptoms in schizophrenia: a comparative analysis of patients with borderline personality disorder and healthy controls. Psychopathology 2004; 37: 281-284 (Pubitemid 39664281)
11. Conus P, Cotton S, Schimmelmann BG, McGorry P & Lambert M. The First-episode Psychosis Outcome Study (FEPOS): Pre-morbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. Early Intervention in Psychiatry 2007; 1(2): 191-200.
12. Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mastele A, Wehmeier PM: Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008; 18: 54-69. (Pubitemid 351311238)
13. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H: Long-term course of adolescent schizophrenia. Schizophrenia Bull 2005; 31: 769-780
14. Gattaz WF, Geuppert MS, Linde I, Diehl A, Hubrich P, Maras A, Dittmann RW: Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: A randomized double-blind trial. Pharmacopsychiatry 2004; 37: 279-285 (Pubitemid 39587055)
15. Gerlach M, Hünnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement H-W, Fegert JM, Wewetzer Ch, Mehler-Wex C: Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 2007; 40: 72-76 (Pubitemid 46697678)
16. Günter M: Pure gold of psychoanalysis or pure chemistry. How can we handle the counter-transference and the psychoanalyst's super-ego conflicts in combined treatment? Psychoanalytic Psychotherapy 2005; 19: 193-204.
17. Günter M: Traumatischer Objektverlust, psychotische Übertragung und Realitätskontrolle. Was bringt eine psychoanalytisch orientierte Frühbehandlung schwerer juveniler Psychosen? Psyche - Zeitschrift für Psychoanalyse 61, 2007: 195-217.
18. Günter M: «Was bedeutet das furchtbare Gefühl der Leere?» Ellen Wests Erkrankung: Polymorphe Form der Schizophrenia simplex oder Borderline-Persönlichkeitsstörung. In: Hirschmüller A (Hrsg.), Ellen West und Ludwig Binswanger. Zur Lebens- und Krankheitsgeschichte einer hochbegabten anorektischen Patientin. Kröning: Asanger 2003, 181-196.
19. Häßler F, Schmelich C, Buchmann J, Bohne S, Schläfke D, Fegert JM: Der Verlauf juveniler Psychosen - eine 46-Jahre Katamnesestudie. Krankenhauspsychiatrie 2004; 15: 60-64 (Pubitemid 38979126)
20. Kaiser S, Roth A, Rentrop M, Friederich HC, Bender S, Weisbrod M: Intra-individual reaction time variability in schizophrenia, depression and borderline personality disorder. Brain Cogn 2008; 66: 73-82. (Pubitemid 351172554)
21. Karle M: Pseudologie oder Schizophrenie? Kinderanalyse 2006; 14: 277-287
22. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann BG, Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007; 68: 75-80. (Pubitemid 46220127)
23. Kluge M, Wehmeier PM, Dittmann RW, Langer F, Czekalla J, Lehmann M, Kessler FH, Beyenburg S, Naber D: A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: Changes in psychopathology and subjective well-being. Pharmacopsychiatry 2005; 38: 6-12. (Pubitemid 40278639)
24. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG: The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141-148 (Pubitemid 41003193)
25. Lambert M, Conus P, Naber D, McGorry P & Schimmelmann BG. Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone. Int J Psychiatry Clin Pract 2005; 9(4): 244-250. (Pubitemid 41658659)
26. Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H, Schacht M, Edwards J, Naber D, McGorry PD: Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005; 38: 206-213 (Pubitemid 41414866)
27. Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG: Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007; 115: 106-113 (Pubitemid 46114871)
28. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J: Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690-1697 (Pubitemid 44955148)
29. Mann K, Rossbach W, Müller MJ, Müller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C: Nocturnal hormone profiles in schizophrenic patients treated with olanzapine. Psychoneuroendocrinology 2006; 31: 256-264 (Pubitemid 41740445)
30. Mann K, Rossbach W, Müller MJ, Müller-Siecheneder F, Russ H, Dittmann RW: Heart rate variability during sleep in schizophrenic patients treated with olonzapine. Int Clin Psychopharm 2004; 19: 325-330. (Pubitemid 39506986)
31. Mehler-Wex C, Duvigneau J, Hartl R, Ben-Shachar D, Warnke A, Gerlach M: Increased mRNA levels of the mitochondrial complex I 75-kDa subunit. A potential peripheral marker of early onset schizophrenia? Eur Child Adolesc Psychiatry. 2006; 15: 504-507
32. Meng H, Schimmelmann BG, Mohler B, Lambert M, Branik E, Koch E, Karle M, Strauss M, Preuss U, Amsler F, Riedesser P, Resch F, Bürgin D. Pretreatment social functioning predicts 1-year outcome in early onset psychosis. Acta Psychiatr Scand 2006; 114: 249-256 (Pubitemid 44379125)
33. Morley KI, Cotton SM, Conus P, Lambert M, Schimmelmann BG, McGorry PD, Foley DL. Familial psychopathology in the First Episode Psychosis Outcome Study. Aust N Z J Psychiatry 2008; 42: 617-626 (Pubitemid 352015740)
34. Müller MJ, Rossbach W, Roeschke J, Müller-Siecheneder F, Bluemler M, Wetzel H, Russ H, Dittmann RW, Benkert O: Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry 2004; 37: 157-162. (Pubitemid 38916423)
35. Murray GK, Clark L, Corlett PR, Blackwell AD, Cools R, Jones PB, Robbins TW, Poustka L. Incentive motivation in first-episode psychosis: A behavioural study. BMC Psychiatry 2008; 8: 34. (Pubitemid 351780129)
36. Naber D, Bandelow B, Bender S, Klimke A, Kühn KU, Lambert M, Lemmer W, Riedel M, Vorbach EU, Dittmann RW: Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005; 111: 106-115 (Pubitemid 40293177)
37. Oades RD, Röpcke B, Henning U, Klimke A. Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity. Behav Brain Funct 2005; 1: 14. (Pubitemid 44848781)
38. Oades RD, Wild-Wall N, Juran SA, Sachsse J, Oknina LB, Röpcke B. Auditory change detection in schizophrenia: sources of activity, related neuropsychological function and symptoms in patients with a first episode in adolescence, and patients 14 years after an adolescent illness-onset. BMC Psychiatry 2006; 6: 7. (Pubitemid 44082047)
39. Oknina LB, Wild-Wall N, Oades RD, Juran SA, Röpcke B, Pfueller U, Weisbrod M, Chan E, Chen EY. Frontal and temporal sources of mismatch negativity in healthy controls, patients at onset of schizophrenia in adolescence and others at 15 years after onset. Schizophr Res. 2005; 76: 25-41. (Pubitemid 40824558)
40. Reichert A, Kreiker S, Mehler-Wex C: The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolescent Psychiatry Mental Health 2008; 2: 8. (Pubitemid 351827646)
41. Remschmidt H, Martin M, Fleischhaker C, Theisen FM, Hennighausen K, Gutenbrunner C, Schulz E: Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm 2007; 114: 505-512 (Pubitemid 46474859)
42. Remschmidt H, Wolf-Ostermann K, Mattejat F: Schizophrene Erkrankungen im Jugendalter: Eine versorgungsepidemiologische Untersuchung an 305 konsekutiven stationären Behandlungsfällen. Nervenarzt 2004; 75: 663-674 (Pubitemid 39118342)
43. Röpcke B, Eggers C. Early-onset schizophrenia: a 15-year follow-up. Eur Child Adolesc Psychiatry. 2005; 14: 341-350
44. Roth A, Roesch-Ely D, Bender S, Weisbrod M, Kaiser S: Increased event-related potential latency and amplitude variability in schizophrenia detected through wavelet-based single-trial analysis. Int J Psychophysiol 2007; 66: 244-254 (Pubitemid 350180129)
45. Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M: Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007; 95: 1-8. (Pubitemid 47315740)
46. Schimmelmann BG, Conus P, Schacht M, McGorry P, Lambert M: Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry. 2005; 66: 1239-1246 (Pubitemid 41546503)
47. Schimmelmann BG, Conus P, Schacht M, McGorry P, Lambert M: Predictors of service disengagement in first-admitted adolescents with psychosis. J Am Acad Child Adolesc Psychiatry 2006; 45: 990-999 (Pubitemid 44126874)
48. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P: Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008; 42: 982-990
49. Schimmelmann B, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner H, Gierow B, Maier J, Meyer E, Schulte-Markwort M: A prospective 12 week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adol Psychopharm 2007; 17: 768-778 (Pubitemid 351158602)
50. Schimmelmann BG, Moritz S, Karow A, Schäfer I, Bussopulos A, Golks D, Krausz M, Naber D & Lambert M. Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005; 9(2): 94-98. (Pubitemid 40874103)
51. Schimmelmann BG, Paulus S, Schacht M, Tilgner C, Schulte-Markwort M, Lambert M: Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005; 15: 249-258 (Pubitemid 40734104)
52. Schimmelmann BG, Schacht M, Perro C & Lambert M. Die initial dysphorische Reaktion auf die Ersteinnahme von Neuroleptika. Nervenarzt 2004; 75: 36-43. (Pubitemid 38258218)
53. Sevecke K, Dreher J, Walger P, Junglas J, Lehmkuhl G: Aggressives Verhalten und Substanzmittelkonsum bei an Schizophrenie erkrankten Jugendlichen im Vergleich zu dissozialen Jugendlichen, eine follow-up Studie. Zeitsch Kinder-Jugendpsych Psychother 2005; 33: 105-112 (Pubitemid 40577189)
54. Smesny S, Klemm S, Stockebrand M, Grunwald S, Gerhard UJ, Rosburg T, Sauer H, Blanz B: Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2006; 77: 79-85. (Pubitemid 47539106)
55. Wagner M, Baving L, Berg P, Cohen R, Rockstroh B: An ERP investigation of semantic priming, repetition priming, and negative priming in schizophrenic patients. J Psychophysiol 2006; 20: 195-211. (Pubitemid 44275446)
56. Wehmeier PM, Barth N, Remschmidt H: Induced delusional disorder: A review of the concept and an unusual case of folie à familie. Psychopathology 2003; 36: 37-45. (Pubitemid 36407937)
57. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, Lambert M: Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. J Psychiatr Res 2008; 42: 676-683 (Pubitemid 351635797)
58. Bachmann S, Resch F, Mundt C: Psychological treatments for psychosis: history and overview. J Am Acad Psychoanal Dyn Psychiatry 2003; 31: 155-176. (Pubitemid 36459213)
59. Bender S, Weisbrod M, Resch F: Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia? J Neural Transm 2007; 114: 1199-1215
60. Bergemann N, Mundt C, Parzer P, Runnebaum B, Resch F: Hypoestrogenism and estrogen replacement therapy in women suffering from schizophrenia. In: Bergemann N, Richer-Rössler A (Hrsg) Estrogen Effects in Psychiatric Disorders, 2005, Wien: Springer; 123-144.
61. Fegert JM: Ethical and legal problems in treating schizophrenic patients with neuroleptics during childhood and adolescence. Child Adolescent Psychopharmacol News 2003; 8: 5.
62. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry 2003; 36 Suppl 3: S181-90. (Pubitemid 38085135)
63. Mehler-Wex C, Riederer P, Gerlach M: Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 2006; 10: 167-179.
64. Remschmidt H, Theisen FM: Schizophrenia and related disorders in children and adolescents. J Neural Transm 2005: 121-141 (Pubitemid 43066718)
65. Resch F, Meng H, Parzer P, Koch E, Bürgin D: Early detection of psychoses in adolescents: do basic symptoms specifically reflect at-risk states? In: Bürgin D, Meng H, (Hrsg) Childhood and Adolescent Psychosis 2004, Basel: Karger; 27-35.